Profiling of differentially expressed genes in adipose tissues of multiple symmetric lipomatosis

Chen,Ke; Wang,Linghao; Yang,Wenjun; Wang,Changfa; Hu,Gui; Mo,Zhaohui

doi:10.3892/mmr.2017.7437

Profiling of differentially expressed genes in adipose tissues of multiple symmetric lipomatosis

Authors:
- Ke Chen
- Linghao Wang
- Wenjun Yang
- Changfa Wang
- Gui Hu
- Zhaohui Mo
View Affiliations

Affiliations: Department of Endocrinology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China, Department of General Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China
Published online on: September 7, 2017 https://doi.org/10.3892/mmr.2017.7437
Pages: 6570-6579
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple symmetric lipomatosis (MSL) is a rare disorder characterized by aberrant multiple and symmetric subcutaneous adipose tissue accumulation in the face, neck, shoulders, back, chest and abdomen, severely affecting the quality of life of patients. At present, precise MSL etiology and pathogenesis remain to be elucidated. The present study first utilized a digital gene expression technique with a next‑generation sequencing platform to profile differentially expressed genes in three cases of MSL vs. normal control tissue. cDNA libraries from these tissue specimens were constructed and DNA sequenced for identification of differentially expressed genes, which underwent bioinformatic analysis using the Gene Ontology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein‑protein interaction (PPI) network analyses. As a result, a total of 859 differentially expressed genes were identified, including 308 upregulated genes (C19orf80, Apelin, C21orf33, FAM166B and HSD11B2 were mostly upregulated 6.984‑, 4.670‑, 4.412‑, 3.693‑ and 3.561‑fold, respectively) and 551 downregulated genes [FosB proto‑oncogene, AP‑1 transcription factor subunit (FOSB), selectin (SEL) E, RAR related orphan receptor (ROR) B, salt inducible kinase (SIK)1 and epidermal growth factor‑like protein (EGFL)6 were mostly downregulated ‑9.845, ‑8.243, ‑8.123, ‑7.702 and ‑7.664 fold, respectively). The GO functional enrichment analysis demonstrated these differentially expressed genes were predominantly involved in biological processes and cellular components, while the KEGG pathway enrichment analysis demonstrated that ribosome, non‑alcoholic fatty liver disease, human T‑lymphotropic virus type 1 (HTLV‑I) infection and Alzheimer's disease pathways were altered in MSL. The PPI network data demonstrated ubiquitin C (UBC), translocator protein (TSPO), Jun Proto‑Oncogene, AP‑1 Transcription Factor (JUN) and FOS were among these differentially expressed genes that participated in regulation of adipocyte differentiation, although no previous study has linked them to MSL. In conclusion, the present study profiled differentially expressed genes in MSL and identified gene pathways that may be associated with MSL development and progression.

View Figures

View References

1	Brodie BC: Lecture XIV: On Fatty or Adipose TumorsLectures Illustrative of Various Subjects In Pathology and Surgery. Longman, Brown, Green and Longmans; London: pp. 275–282. 1846
2	Nisi G and Sisti A: Images in clinical medicine. Madelung's disease. N Engl J Med. 374:5722016. View Article : Google Scholar : PubMed/NCBI
3	Rendina D, De Filippo G, Nazzaro A and Strazzullo P: Impaired gonadal function in a woman with multiple symmetric lipomatosis. Minerva Endocrinol. 38:211–215. 2013.PubMed/NCBI
4	Palacios E, Neitzschman HR and Nguyen J: Madelung disease: Multiple symmetric lipomatosis. Ear Nose Throat J. 93:94–96. 2014.PubMed/NCBI
5	Esteban J, úlvez L, Perelló Aragonés S and Bargalló X Aguilar: Sleep apnea-hypopnea syndrome and multiple symmetrical lipomatosis. Arch Bronconeumol. 49:86–87. 2013.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
6	Ardeleanu V, Chicos S, Georgescu C and Tutunaru D: Multiple benign symmetric lipomatosis-a differential diagnosis of obesity. Chirurgia (Bucur). 108:580–583. 2013.PubMed/NCBI
7	Yeh NC, Yang CY, Chou CW, Yen FC, Lee SY and Tien KJ: Madelung's disease. J Clin Endocrinol Metab. 97:3012–3013. 2012. View Article : Google Scholar : PubMed/NCBI
8	Tadisina KK, Mlynek KS, Hwang LK, Riazi H, Papay FA and Zins JE: Syndromic lipomatosis of the head and neck: A review of the literature. Aesthetic Plast Surg. 39:440–448. 2015. View Article : Google Scholar : PubMed/NCBI
9	Haap M, Siewecke C, Thamer C, Machann J, Schick F, Häring HU, Szeimies RM and Stumvoll M: Multiple symmetric lipomatosis: A paradigm of metabolically innocent obesity? Diabetes Care. 27:794–795. 2004. View Article : Google Scholar : PubMed/NCBI
10	Chen K, Xie Y, Hu P, Zhao S and Mo Z: Multiple Symmetric Lipomatosis: Substantial subcutaneous adipose tissue accumulation did not induce glucose and lipid metabolism dysfunction. Ann Nutr Metab. 57:68–73. 2010. View Article : Google Scholar : PubMed/NCBI
11	Cojocaru DC, Cozma CD and Postolache P: Markers of insulin resistance in a case of Launois-Bensaude syndrome. Rev Med Chir Soc Med Nat Iasi. 117:404–408. 2013.PubMed/NCBI
12	Brea-García B, Cameselle-Teijeiro J, Couto-González I, Taboada-Suárez A and González-Álvarez E: Madelung's disease: Comorbidities, fatty mass distribution and response to treatment of 22 patients. Aesthetic Plast Surg. 37:409–416. 2013. View Article : Google Scholar : PubMed/NCBI
13	Heike Z, Gudrun UM, Frank RD, Vetter H and Walger P: Multiple benign symmetric lipomatosis-a differential diagnosis of obesity: Is there a rationale for fibrate treatment? Obes Surg. 18:240–242. 2008. View Article : Google Scholar : PubMed/NCBI
14	Verhelle NA, Nizet JL, van den Hof B, Guelinckx P and Heymans O: Liposuction in benign symmetric lipomatosis: Sense or senseless? Aesthetic Plast Surg. 27:319–321. 2003. View Article : Google Scholar : PubMed/NCBI
15	Enzi G, Busetto L, Sergi G, Coin A, Inelmen EM, Vindigni V, Bassetto F and Cinti S: Multiple symmetric lipomatosis: A rare disease and its possible links to brown adipose tissue. Nutr Metab Cardiovasc Dis. 25:347–353. 2015. View Article : Google Scholar : PubMed/NCBI
16	Ballester S, ánchez R, Mira MÁ Navarro, Marco C Pujol and Estrada R Botella: Symmetric benign lipomatosis: Madelung syndrome. Med Clin (Barc). 141:366–367. 2013.(In Spanish). View Article : Google Scholar : PubMed/NCBI
17	Kobayashi J, Nagao M, Miyamoto K and Matsubara S: MERRF syndrome presenting with multiple symmetric lipomatosis in a Japanese patient. Intern Med. 49:479–482. 2010. View Article : Google Scholar : PubMed/NCBI
18	Schoffer K and Grant I: Multiple lipomas, alcoholism, and neuropathy: Madelung's disease or MERRF? Muscle Nerve. 33:142–146. 2006. View Article : Google Scholar : PubMed/NCBI
19	Nisoli E, Regianini L, Briscini L, Bulbarelli A, Busetto L, Coin A, Enzi G and Carruba MO: Multiple symmetric lipomatosis may be the consequence of defective noradrenergic modulation of proliferation and differentiation of brown fat cells. J Pathol. 198:378–387. 2002. View Article : Google Scholar : PubMed/NCBI
20	Plummer C, Spring PJ, Marotta R, Chin J, Taylor G, Sharpe D, Athanasou NA, Thyagarajan D and Berkovic SF: Multiple symmetrical lipomatosis-a mitochondrial disorder of brown fat. Mitochondrion. 13:269–276. 2013. View Article : Google Scholar : PubMed/NCBI
21	Prantl L, Schreml J, Gehmert S, Klein S, Bai X, Zeitler K, Schreml S, Alt E, Gehmert S and Felthaus O: Transcription profile in sporadic multiple symmetric lipomatosis reveals differential expression at the level of adipose tissue-derived stem cells. Plast Reconstr Surg. 137:1181–1190. 2016. View Article : Google Scholar : PubMed/NCBI
22	Chen K, He H, Xie Y, Zhao L, Zhao S, Wan X, Yang W and Mo Z: miR-125a-3p and miR-483-5p promote adipogenesis via suppressing the RhoA/ROCK1/ERK1/2 pathway in multiple symmetric lipomatosis. Sci Rep. 5:119092015. View Article : Google Scholar : PubMed/NCBI
23	Wang L, Feng Z, Wang X, Wang X and Zhang X: DEGseq: An Rpackage for identifying differentially expressed genes from RNA-seq data. Bioinformatics. 26:136–138. 2010. View Article : Google Scholar : PubMed/NCBI
24	Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multipletesting. J R Statist Soc. 57:289–300. 1995.
25	Mao X, Cai T, Olyarchuk JG and Wei L: Automated genome annotation and pathway identification using the KEGG Orthology (KO) as a controlled vocabulary. Bioinformatics. 21:3787–3793. 2005. View Article : Google Scholar : PubMed/NCBI
26	Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, Katayama T, Kawashima S, Okuda S, Tokimatsu T and Yamanishi Y: KEGG for linking genomes to life and the environment. Nucleic Acids Res. 36(Database Issue): D480–D484. 2008.PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Harsch IA, Bergmann T, Koebnick C, Wiedmann R, Ruderich F, Hahn EG and Konturek PC: Adiponectin, resistin and subclinical inflammation-the metabolic burden in Launois Bensaude Syndrome, a rare form of obesity. J Physiol Pharmacol. 58 Suppl 1:S65–S76. 2007.
29	Ouchi N: Adipocytokines in cardiovascular and metabolic diseases. J Atheroscler Thromb. 23:645–654. 2016. View Article : Google Scholar : PubMed/NCBI
30	Matsuzawa Y: Therapy insight: Adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med. 3:35–42. 2006. View Article : Google Scholar : PubMed/NCBI
31	Ryu KY, Maehr R, Gilchrist CA, Long MA, Bouley DM, Mueller B, Ploegh HL and Kopito RR: The mouse polyubiquitin gene UbC is essential for fetal liver development, cell-cycle progression and stress tolerance. EMBO J. 26:2693–2706. 2007. View Article : Google Scholar : PubMed/NCBI
32	Dikic I, Wakatsuki S and Walters KJ: Ubiquitin-binding domains-from structures to functions. Nat Rev Mol Cell Biol. 10:659–671. 2009. View Article : Google Scholar : PubMed/NCBI
33	Ciechanover A: Intracellular protein degradation: From a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Neurodegener Dis. 10:7–22. 2012. View Article : Google Scholar : PubMed/NCBI
34	Wójcik C, Lohe K, Kuang C, Xiao Y, Jouni Z and Poels E: Modulation of adipocyte differentiation by omega-3 polyunsaturated fatty acids involves the ubiquitin-proteasome system. J Cell Mol Med. 18:590–599. 2014. View Article : Google Scholar : PubMed/NCBI
35	Santoro A, Raso G Mattace, Taliani S, Da Pozzo E, Simorini F, Costa B, Martini C, Laneri S, Sacchi A, Cosimelli B, et al: TSPO-ligands prevent oxidative damage and inflammatory response in C6 glioma cells by neurosteroid synthesis. Eur J Pharm Sci. 88:124–131. 2016. View Article : Google Scholar : PubMed/NCBI
36	Wyatt SK, Manning HC, Bai M, Ehtesham M, Mapara KY, Thompson RC and Bornhop DJ: Preclinical molecular imaging of the translocator protein (TSPO) in a metastases model based on breast cancer xenografts propagated in the murine brain. Curr Mol Med. 12:458–466. 2012. View Article : Google Scholar : PubMed/NCBI
37	Repalli J: Translocator protein (TSPO) role in aging and Alzheimer's disease. Curr Aging Sci. 7:168–175. 2014. View Article : Google Scholar : PubMed/NCBI
38	Cumming P and Borghammer P: Molecular imaging and the neuropathologies of Parkinson's disease. Curr Top Behav Neurosci. 11:117–148. 2012. View Article : Google Scholar : PubMed/NCBI
39	Qi X, Xu J, Wang F and Xiao J: Translocator protein (18 kDa): A promising therapeutic target and diagnostic tool for cardiovascular diseases. Oxid Med Cell Longev. 2012:1629342012. View Article : Google Scholar : PubMed/NCBI
40	Li F, Liu J, Liu N, Kuhn LA, Garavito RM and Ferguson-Miller S: Protein 18 kDa (TSPO): An Old protein with new functions? Biochemistry. 55:2821–2831. 2016. View Article : Google Scholar : PubMed/NCBI
41	Dimitrova-Shumkovska J, Veenman L, Ristoski T, Leschiner S and Gavish M: Chronic high fat, high cholesterol supplementation decreases 18 kDa translocator protein binding capacity in association with increased oxidative stress in rat liver and aorta. Food Chem Toxicol. 48:910–921. 2010. View Article : Google Scholar : PubMed/NCBI
42	Lecanu L, Yao ZX, McCourty A, Sidahmed el-K, Orellana ME, Burnier MN and Papadopoulos V: Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction amino acid sequence of the translocator protein TSPO. Steroids. 78:137–146. 2013. View Article : Google Scholar : PubMed/NCBI
43	Wagner EF and Eferl R: Fos/AP-1 proteins in bone and the immune system. Immunol Rev. 208:126–140. 2005. View Article : Google Scholar : PubMed/NCBI
44	Kveiborg M, Sabatakos G, Chiusaroli R, Wu M, Philbrick WM, Horne WC and Baron R: DeltaFosB induces osteosclerosis and decreases adipogenesis by two independent cell-autonomous mechanisms. Mol Cell Biol. 24:2820–2830. 2004. View Article : Google Scholar : PubMed/NCBI
45	Luther J, Driessler F, Megges M, Hess A, Herbort B, Mandic V, Zaiss MM, Reichardt A, Zech C, Tuckermann JP, et al: Elevated Fra-1 expression causes severe lipodystrophy. J Cell Sci. 124:1465–1476. 2011. View Article : Google Scholar : PubMed/NCBI